

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A23L 1/00	A2	(11) International Publication Number: WO 00/11965 (43) International Publication Date: 9 March 2000 (09.03.00)
(21) International Application Number: PCT/GB99/02845 (22) International Filing Date: 27 August 1999 (27.08.99)		(74) Agents: HUMPHREYS, Ceris, Anne et al.; Abel & Imray, 20 Red Lion Street, London WC1R 4PQ (GB).
(30) Priority Data: 9818913.7 28 August 1998 (28.08.98) GB 9827243.8 10 December 1998 (10.12.98) GB		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(71) Applicant (for all designated States except US): THE UNIVERSITY OF BATH [GB/GB]; Claverton Down, Bath BA2 7AY (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): BLAKE, David, Russell [GB/GB]; The Ground Floor Flat, 16 The Circus, Bath BA1 2ET (GB). STEVENS, Clifford, Robert [GB/GB]; 49 The Old Batch, Bradford on Avon, Wiltshire BA15 1TL (GB). EISENTHAL, Robert [GB/GB]; 20 Lansdown Lane, Bath BA1 4LR (GB). HARRISON, Roger [GB/GB]; 16 Grove Leaze, Bradford on Avon, Wiltshire BA15 1PH (GB). MILLAR, Timothy, Mark [GB/GB]; 139 Langdon Road, Southdown, Bath BA2 1LT (GB). EDWARDS, Rachel [GB/GB]; 2 Southville Road, Bradford on Avon, Wiltshire BA15 1HP (GB).		

(54) Title: INGESTIBLE COMPOSITIONS COMPRISING ANTIBACTERIAL AGENTS



(57) Abstract

A formulation for use as a bactericidal agent in the human or animal digestive system includes xanthine oxidoreductase. The formulation may especially be in the form of a formula feed formulation or enteral feed formulation for administration to a human or animal. The formulation is capable of functioning as a "natural antibiotic" to prevent or reduce bacterial infection within the gut, especially the neonatal gut.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

Ingestible compositions comprising
antibacterial agents

5 The present invention relates to compositions comprising xanthine oxidoreductase (XOR). In particular, but not exclusively, the invention relates to the use of a composition comprising XOR as a feed for humans or animals, and finds special application in relation to 10 formula feed for babies.

10 The enzyme xanthine oxidoreductase (XOR) is a complex molybdoflavoprotein, the action of which has been studied for many years.

15 XOR is a major protein component of the membrane surrounding fat droplets in whole milk. Consequently, cows' milk is a rich and convenient source of the enzyme, as has been known for many years. XOR has also been characterised from rat, chicken and turkey livers. More recently, human milk has been found to contain XOR, which 20 has now been purified from that source. Initial research shows that, while the human milk XOR enzyme has similar physicochemical properties to the bovine milk enzyme, the human enzyme shows differences in its catalytic activity.

25 The purpose of XOR in milk has never been fully ascertained. One suggestion has been that it provides a source of molybdenum and iron, metals potentially useful for the developing neonate.

30 There have also been suggestions that XOR has a role in the production of bactericidal agents. As discussed further below, XOR can catalyse the production of superoxide and hydrogen peroxide, which are known bactericidal agents. As indicated below, however, in the low oxygen concentrations found in the gut, it is thought

unlikely that bactericidal levels of superoxide or hydrogen peroxide will be attained.

The role of XOR in the development of gout has been the subject of extensive study. XOR is involved in the catabolism of purines to uric acid, catalysing the oxidation of hypoxanthine to xanthine and xanthine to uric acid. Compositions have been developed which block the action of XOR and which are useful in the prevention and treatment of gout.

XOR exists in two inter-convertible forms, xanthine dehydrogenase (XDH, EC 1.1.1.204) and xanthine oxidase (XO, EC 1.1.3.22). XDH, which is believed to predominate *in vivo*, preferentially reduces NAD⁺, whereas XO does not reduce NAD⁺, preferring molecular oxygen.

Where reference is made herein to xanthine oxidoreductase, it should be understood that that term refers to both xanthine dehydrogenase (XDH) and xanthine oxidase (XO), where appropriate. It will be appreciated that references to XOR further include references to analogs of xanthine oxidoreductase that have xanthine oxidoreductase activity. Such analogs may include but are not limited to, for example, xanthine oxidoreductase which has been modified chemically or otherwise, analogs having fragments of xanthine oxidoreductase derived from naturally-occurring enzyme, and analogs having polypeptides obtained by replication of the enzyme or a portion thereof using any suitable biotechnological method, provided in each case that the catalytic activity of the endogenous xanthine oxidoreductase is retained at least to an appreciable extent.

XOR can also effect reduction of molecular oxygen. That reaction generates the reactive oxygen species superoxide anion and hydrogen peroxide.

The superoxide radicals thus generated have been implicated in relation to chronic inflammatory intestinal diseases such as Crohn's disease and colitis ulcerosa. US 5,484,605 describes the administration of oxypurinol to the intestine to inhibit xanthine oxidase, thus preventing the formation of superoxide radicals which are believed to act as inflammatory mediators.

It has been reported, Millar, T.M. et al, FEBS Letters 427 (1998) 225-228, that, under hypoxic conditions and in the presence of NADH, XOR is capable of catalysing the reduction of glyceryl trinitrate (GTN), as well as inorganic nitrate and nitrite, to nitric oxide (NO).

Nitric oxide (NO) is widely recognised as mediating the relaxation of smooth muscle in vasodilation and as initiating many other important biological functions, including inhibition of platelet aggregation and adhesion. Its generally accepted physiological source is NO synthase, a complex enzyme which is totally dependent on oxygen for its activity and consequently ineffective in a hypoxic environment, where the vasodilatory properties of NO might be seen to be advantageous.

Babies who are not breast-fed are fed what is referred to herein as formula feed. Such formula feed has a composition which commonly includes sources of protein, fat and carbohydrate as well as minerals and are generally formulated to be nutritionally complete. Many formula feeds are based on cow's milk while some others are soy based. The term "formula feed" used herein should be understood to cover both formulations based on milk products as well as those based on soya or other products and which may or may not be nutritionally

complete. The formula feed commonly takes the form of a dried powder which is reconstituted before being fed to the baby. Alternatively, the formula feed may be in liquid form either as a concentrated liquid requiring dilution or as a ready-to-feed formulation.

5 Enteral feeding may be prescribed where a patient is unable to eat normally, or has severe malabsorption or malnourishment. Enteral feed may take the form of tube and sip feeds. The enteral feed may be nutritionally 10 complete and generally comprises protein, carbohydrate and fat as well as vitamins and minerals. The term "ental feed" used herein should be understood to cover both formulations based on milk products as well as those based on soya or other products and which may or may not 15 be nutritionally complete. The enteral feed may be in liquid form or may be in the form of a powder which is reconstituted before use. In many cases the enteral feed formulation is based on the composition of the neonatal formula feed.

20 The present invention provides a formulation for use as a bactericidal agent in the human or animal digestive system, the formulation including active xanthine oxidoreductase.

25 More particularly, in accordance with the invention, there is provided a formula feed formulation or enteral feed formulation for administration to a human or animal, the formulation including active xanthine oxidoreductase (XOR).

30 The term "feed" is used herein to include both enteral feeds and formula feeds.

We have found that the active enzyme xanthine oxidoreductase (XOR) is absent from formula feeds and from enteral feeds. It is thought that that is because

XOR is either absent from the feed or it is inactivated as a result of the treatment process used in the production of feeds. Where reference is made herein to "active" XOR and "active" enzyme, it is to be understood that reference is made to XOR and enzyme which has not, for example, been inactivated or broken down in such a way.

Up to now, it would have been thought that the addition of active XOR to feeds would be unnecessary and undesirable. The only roles of XOR previously known, as indicated above, were as a general "housekeeping" enzyme in the catabolism of purines, which may also have a pathological role in the development of gout and of chronic inflammatory intestinal diseases. The only other beneficial role of XOR was thought to be as a source of molybdenum and iron. It was thought (correctly) that those minerals could still be obtained from inactivated XOR, which might be present in feed.

We have now found that the addition of active XOR to feed is potentially beneficial in killing pathogenic intestinal bacteria. The active XOR may thus be regarded as a "natural antibiotic", that is, a substance of natural origin which is capable of destroying or inhibiting the growth of at least some strains of pathogenic micro-organism. It is believed that feed containing active XOR will be beneficial in the mitigation of intestinal infection and necrotising enterocolitis in the neonate fed with formula feed. Sick adults that are enterally fed are also at risk of the same complications as children fed formula feed.

Studies have shown that babies who are fed with formula feed are about twenty times more likely to suffer from gastrointestinal (GI) infection than babies who are

breast fed. The reason for that discrepancy has not been known.

In the presence of oxygen, as stated above, XOR can generate superoxide and hydrogen peroxide. However, 5 the amount of oxygen available in the gut is generally very low and bactericidal levels of superoxides or hydrogen peroxide are unlikely to be attained.

As discussed above, it has been found that the catalysis by XOR of the reduction of glycetyl trinitrate (GTN), as well as inorganic nitrate and nitrite, to 10 nitric oxide (NO) occurs under hypoxic conditions. It is such hypoxic conditions which are present in the gut.

We have also found that the optimum pH for the production of NO under the hypoxic conditions is about 15 pH 5.5. It is known that the pH of the neonatal stomach normally ranges between pH 3.5 and 6. Thus, we have found that the neonatal stomach presents an environment in which the production of NO in the presence of XOR is at a peak. Furthermore, it is at pH levels above about 4 20 at which pathogenic bacteria are more active than at lower pH of about 2 normally found in the adult stomach. Thus it is believed that the neonatal stomach, having a relatively high pH, is at particular risk from pathogenic bacteria. Furthermore, it is found that, for example in 25 post-operative adults, the pH of the stomach rises to above 4. It has also been noted that post-operative adults have a relatively high risk of GI infection.

Thus, surprisingly, we have found under the 30 conditions of the neonatal gut, XOR can catalyse the production not only of superoxide, but of NO. Superoxide and NO rapidly interact to generate peroxynitrite, a much more potent bactericidal species than superoxide, NO or hydrogen peroxide. While superoxide has some

bactericidal properties and in some situations NO has also been found to kill or damage bacteria, it is the interaction of superoxide and NO to form peroxynitrite and other products which is believed to give superior 5 bactericidal action. Peroxynitrite (and, it is thought, other products of the interaction of superoxide and NO) are particularly potent bactericidal species.

The concentration of nitrite present in the neonatal gut is normally low, and it might therefore be thought 10 that the potential for XOR-catalysed generation of NO would be limited. It is believed however that, the known affinity of XOR for acidic polysaccharides such as those occurring in bacterial capsules causes XOR to become more concentrated in the immediate vicinity of bacteria. In 15 anaerobic environments, bacteria commonly are found to excrete nitrite and thus the association of XOR with the bacteria may have the result that the XOR will be located in a localised region of elevated nitrite concentration.

In one embodiment of the invention, the formulation 20 is for use as formula feed. As indicated above, the use of XOR finds particular application in relation to the feeding of neonates.

Alternatively, the formulation is for use as an enteral feed for adults.

25 While reference is made herein to the feeding of humans, the invention is also of particular relevance in the feeding of animals and the terms "formula feed", "enteral feed" and "feed" should be understood to include formulations for animals. The invention finds particular 30 application in respect of mammals.

Animals also suffer from GI infection, in particular Scours disease (diarrhoea in neonatal animals). Scours disease is a particular problem for calves and pigs taken

from their mothers soon after birth. For calves and pigs taken from their mothers up to ten days after birth and fed waste milk or formula feed, the mortality rate can be as much as 80%. In some cases, Scours disease can be 5 cured by administering electrolyte solutions but such treatment is very expensive.

It is thought that the addition of active XOR to feed for animals will mitigate GI infections, in particular Scours disease.

10 The formulation may advantageously include an amount of active XOR which is such that the active XOR concentration in the formulation is at least as large as the normal physiological concentration of XOR, for example in milk. Preferably, the concentration of the XOR exceeds the normal physiological concentration of XOR. 15 Advantageously, the formulation includes from 50 to 500 μ g/ml of XOR, based on the volume of the formulation (when ready-to-use, having been diluted if necessary). Preferably the formulation includes from 50 to 150 μ g/ml 20 which is comparable to the level of XOR found in natural breast milk. In some cases, it may be desirable to increase or reduce the amount of active XOR in the feed, for example, as a function of the baby's age and/or the incidence of GI infection.

25 We have found that a particularly advantageous source of active XOR is buttermilk, in particular lyophilised buttermilk.

In some cases it is thought that the addition of XOR 30 in purified or other form will be desirable, for example where there is a risk of allergy to buttermilk.

The formula feed and/or the enteral feed including the active XOR in accordance with the invention may be in

the form of a powder or may be in liquid form ready for feeding to the patient.

As indicated above, it is believed that for the formula feed and enteral feed formulations, any active XOR which was naturally present in those formulations is destroyed or deactivated during the manufacture of the formulation, possibly as a result of heat treatment. In a particularly preferred embodiment of the invention, one portion of the formula or enteral feed is prepared in the standard way, for example including heat treatment step(s). A composition comprising active XOR is subsequently added to the prepared portion. That addition of the XOR may be carried out by a manufacturer, or may be carried out, for example, immediately prior to use of the formulation. For example, in the case of a powdered feed which is made up with water prior to use, a powdered composition comprising the active XOR may be contained in a separate container from that of the rest of the formulation, for example in a sachet.

Alternatively, the portion including the active XOR may be in tablet form or may be contained in a capsule. The rest of the feed may be made up in the normal way, for example by the addition of hot water and shaking, and the XOR composition added once the rest of the feed has been prepared. That is of particular importance in the case in which the normal method of making up of the formulation might deactivate the XOR, for example as a result of the addition of boiling water. Where the making up of the formulation would not damage the activity of the XOR, or where the formulation is sold ready-prepared, the XOR composition and the rest of the formulation may be provided together as a mixture.

Thus the invention provides a combination product for use in the preparation of a formulation in which the product comprises two separate portions, the first portion including active XOR and the second portion comprising substantially no active XOR.

5 In one embodiment of the invention, the second portion of the formulation is in the form of a powder.

As indicated above, the second portion may have been treated by heat treatment, for example UHT treatment, in 10 the normal way, thus deactivating the XOR.

In a particularly preferred embodiment of the invention, the active XOR is added in the form of buttermilk. The first portion may be pasteurised. As indicated above, pasteurisation has been found not to 15 deactivate XOR.

As indicated above, advantageously, the first portion is in a first container, the second portion is in a second container. Thus the two portions can be held separate until use. For example, where both portions are 20 in the form of a powder, each powder portion can be made up separately using different methods before being mixed together. For example, the first portion might be made up with cold water and the second portion may be made up with boiling water. Alternatively, the first portion may 25 be in the form of a liquid ready for mixing into the second portion of the formulation once the second portion has been made up.

Advantageously, the formulation further includes electron donors and/or electron acceptors. Examples of 30 electron donors are purines and nitrogen-containing heterocyclic compounds, for example hypoxanthine, NADH. Examples of electron acceptors are organic and inorganic nitrates and nitrites.

According to the invention, there is also provided a composition for addition to a formulation for use as feed, the composition comprising active XOR. It is envisaged that the composition containing the active XOR might be sold separately from the formula or enteral feed, the composition being for addition to the feed prior to use.

Advantageously, the composition comprises buttermilk. As indicated above, buttermilk is a particularly preferred source of active XOR. Lyophilised buttermilk may be used. It may be preferable, however, for the buttermilk to be spray-dried by spraying the buttermilk into air at a temperature which is so selected that the activity of the XOR is wholly or at least substantially retained. In general, to avoid any detrimental effect on the activity of XOR, heat treatment steps that may be used in the treatment of XOR-containing compositions or formulations should preferably be such that the temperature of the composition or formulation does not exceed 65°C.

The composition may be in the form of a powder.

Advantageously, the composition further includes electron donors and/or electron acceptors. Examples of electron donors are purines and nitrogen-containing heterocyclic compounds, for example hypoxanthine, NADH. The nature of the electron donor may influence the rate of generation of bactericidal species. For example, use of hypoxanthine as electron donor results in a more rapid, but less prolonged generation of bactericidal species than NADH. Examples of electron acceptors are organic and inorganic nitrates and nitrites.

According to the invention, there is also provided, a method of making a formulation for use as feed, the

method comprising the step of adding a composition comprising active XOR.

The method advantageously comprises the steps of:

- a. preparing a first portion of the formulation, the first portion comprising a composition including active XOR; and
- b. preparing a second portion of the formulation, the first portion and second portion being separate from each other for subsequent mixing to form the formulation.

Advantageously, the first portion comprises buttermilk, preferably lyophilised buttermilk. As indicated above, the buttermilk may include additives.

Preferably, the second portion comprises a sterilised feed composition.

Also provided by the invention is the use of active XOR in the treatment of gastrointestinal (GI) infection. The invention also provides the use of active XOR in the treatment of Scours disease.

Additionally provided is the use of active XOR in the killing of bacteria.

The invention also provides a method of feeding a patient with enteral feed, in which the enteral feed includes active XOR and also a method of feeding a neonate with formula feed, in which the formula feed includes active XOR.

Also provided is a method of treatment of gastrointestinal infection using active XOR.

It will be appreciated that XOR used in accordance with the invention may be of any biological origin, for example of mammalian or other animal origin, or originating from a suitable micro-organism, for example,

aspergillus sp. XOR of ruminant origin offers the advantage of ready availability.

The invention will now be explained in more detail with reference to the accompanying drawings, of which:

5 Fig. 1 is a graph illustrating the effect of peroxy nitrite on cell viability, under the conditions of Test 8(a);

10 Fig. 2 is a graph illustrating the effect of added peroxy nitrite on cell colony growth in semi-skimmed-bovine milk, as determined in Test 8(b);

Fig. 3 is a graph illustrating the dependence of XO-mediated killing of cells as determined in Test 8(c);

15 Fig. 4 is a graph showing the effects of hypoxanthine addition on bacterial growth in pasteurised milk;

Fig. 5 is a graph showing the effect of XO concentration on bacterial growth rate;

Fig. 6 is a graph showing the dependence of cell growth inhibition on hypoxanthine concentration;

20 Fig. 7 is a graph showing the effect of oxypurinol on XO/hypoxanthine-related growth inhibition; and

Fig. 8 is a graph showing the effect of hypoxanthine at various concentrations on growth inhibition.

25

Determination of nitric oxide production

The production of nitric oxide in the following tests and examples was analysed using an ozone chemiluminescence assay in a continuous flow apparatus (Sievers NOA 280) that allows the real time analysis of NO production. The apparatus was modified to allow a constant stream of nitrogen to flow into the reaction chamber. Chemiluminescence data were collected by a data

acquisition system; the mean NO produced in parts per billion (ppb) was calculated from readings taken every second and shown as ppb or mV.

Progress curves, of molar production of NO against time, were calculated by taking into account the gas flow and the mean level of NO. Molar production of NO was expressed as ppb/sec or mV/sec. Reactions were carried out in a final volume of 1 ml at 37°C in an atmosphere of < 1% oxygen (Stathkelvin combination needle oxygen electrode, Diamond General Corp.).

The method used was as follows:

(a) Two clean 7ml bijous were obtained, one for each of the "substrates" and the "milk".

To the "substrates" bijou, 200 μ l of 100mM stock sodium nitrite was added together with 200 μ l of the 5mM reduced NADH to give an assay concentration of 20mM nitrite and 1mM reduced NADH.

To the "milk" bijou were added 600 μ l of milk sample to give an assay volume of 1ml.

(b) Using a flow rate of 200ml/min, each bijou mixture and a corresponding injection needle was degassed with nitrogen gas (N_2) for about 10 seconds and the bijou was capped.

(c) The reaction cell comprised a 7ml screw-cap bijou having three needle holes in its cap. A continuous flow of warmed N_2 (200ml/min flow rate) was injected into the bijou through one of the needle holes in the cap to give the required hypoxic conditions. The reaction cell was held at a temperature of 37°C in a water bath mounted on a magnetic stirrer. A magnetic flea was placed in the reaction cell to mix the samples once injected.

(d) Samples of NO were taken from the reaction cell by a needle that was connected to a Sievers Nitric Oxide

Analyser (NOA-280) and the results were recorded for analysis using a computer.

(e) At time (t) 0 minutes, the NOA-280 started the measurement of NO from the reaction cell. At t=1 minute, 5 the contents of the "substrates" bijou were injected into the reaction cell using a 1ml syringe and the background NO was measured.

(f) At t=5 minutes, the contents of the "milk" bijou were injected into the reaction cell using a 1ml syringe 10 and the release of NO was monitored for a further 20 minutes. The set up was such that the reaction cell was a sealed system having an inlet gas flow of 200ml/min and a sample extraction flow to the NOA-280 of 200ml/min. The steady-state generation of NO (which corresponded to 15 a plateau region on the trace of the NO production) was noted to give the mV/s release of NO from the 1ml assay volume.

The samples were diluted with PBS where necessary to give an assay of 1ml for the test of NO generation.

20

Reagents used

The reagents used in the tests and examples described below were as follows:

1. Bovine xanthine oxidase (XOR) - Biozyme, Blaenavon, UK.

25 This source of enzyme had a concentration of 10.7mg/ml and was batch 104AX

2. Sodium nitrite (NaNO_2) - Sigma Chemicals (Sigma-Aldrich Company Ltd.), Poole, UK. This was dissolved in 1X Phosphate Buffered Saline (PBS), pH 7.3, to the 30 required concentration.

3. β -Nicotinamide Adenine Dinucleotide, reduced form, (β -NADH) - Sigma Chemicals.

4. Phosphate Buffered Saline (PBS) - Oxoid Ltd., Basingstoke, UK. Tablets were added in the proportion of 1 per 100ml of distilled water and mixed until thoroughly dissolved to give 1X PBS, pH7.3.
5. 5. Oxypurinol - Sigma Chemicals. A stock 1mM solution was made up by adding 0.0015g to 0.25ml of 1M NaOH. This was mixed until the oxypurinol dissolved. Then 9.75ml of 1X PBS was added and the pH altered until pH7.3 was reached using drops of 1M H₁.
10. 6. Diphenyliodonium (DPI) - ICN Biomedical. A stock 1mM solution was made up by adding 0.0032g to 10ml 1X PBS, pH7.3.
7. Formula milks:
 - a. PreAptamil with Milupan (2.4g protein/100ml) - Milupa, Trowbridge, UK.
 - b. Aptamil First with Milupan (1.5g protein/100ml) - Milupa.
 - c. Farleys First Milk - H.J. Heinz Co. Ltd., Hayes, UK.
 20. d. Cow and Gate Premium (1.4g protein/100ml) - Cow and Gate, Trowbridge, UK.
 - e. Sma Gold 1.5g protein/100ml) - SMA Nutrition, Maidenhead, UK.
 - f. Sma Wysoy (1.8g protein/100ml) - SMA Nutrition.
25. 8. Human Breast Milk. Samples obtained from subjects in the local area
9. Carton milk. Milk bought in pints from the local shop either as full milk or semi-skimmed milk (3.4g protein/100ml). Lordswood Dairy, Bristol, UK was the source of the milk.
30. 10. Untreated cows' milk was obtained from a local farm
11. Buttermilk obtained from Waitrose (John Lewis Partnership, UK).

Test 1

The release of nitric oxide (NO) from a composition including pure bovine xanthine oxidase under hypoxic 5 conditions was studied. The samples studied comprised reduced β -Nicotinamide adenine dinucleotide (NADH) and nitrite (NO_2^-) and pure bovine xanthine oxidase.

Bovine xanthine oxidase was diluted with PBS as indicated 10 in Table 1 below to give 300 μl of enzyme mixture. The enzyme mixture (300 μl) was mixed with 700 μl of a substrate mixture to give an assay volume of 1 ml. The substrate mixture comprised nitrite which was added to the assay to give a concentration of 1mM and NADH which 15 was added to give a concentration of 0.3mM. Where, for example in Tests 2 to 4 below, additional components are added to the sample, the amount of PBS is adjusted accordingly to give an assay volume of 1 ml. The total XOR protein in the assay is shown in Table 1. The sample 20 was placed in the reaction vessel of the NO determination apparatus under a nitrogen atmosphere and the generation of NO was measured and the results calculated as a steady state rate in mV/s. The rate of NO release for the different concentrations of XOR is also shown in Table 1.

Table 1

Volume XOR enzyme (μ l)	Volume PBS (μ l)	XOR protein in assay (μ g)	NO release (mV/s)
0	300	0.0	15.10
2	298	21.4	50.05
5	295	53.5	76.35
10	290	107.0	128.55
15	285	160.5	187.20
20	280	214.0	225.75

- 5 Where the pure XOR is used in the samples, NADH was required as a substrate for the reduction of the nitrite to proceed. It is believed that in many cases, where the XOR is added to, for example a formula feed, the addition of a separate electron donor, for example NADH, will not
- 10 be required because suitable substrate species will already be present in the feed and/or in the GI tract of the infant or adult to whom the feed is administered.

Test 2

- 15 Using the method described above in respect of Test 1, the effect of the variation in the concentration of NADH on the production of NO was investigated. 4mM NADH was diluted with PBS to give the relevant concentration. The results are shown in Table 2.

20

Table 2

XOR protein in assay (µg)	NADH concentration in assay (mM)	NO release (mV/s)
53.5	0.00	0.00
53.5	0.10	30.45
53.5	0.25	66.80
53.5	0.50	92.55
53.5	1.00	103.35
53.5	2.00	109.20
107.0	0.00	0.00
107.0	0.10	74.45
107.0	0.25	142.70
107.0	0.50	192.65
107.0	1.00	230.05
107.0	2.00	264.65

5 Test 3

Using the method described above in respect of Test 1, the effect of the variation in the concentration of nitrite on the production of NO was investigated. As for Test 1, the concentration of NADH was 0.3 mM. 1M nitrite (or 100mM nitrite, where appropriate for low concentrations) was diluted with PBS to give the relevant concentration. The results are shown in Table 3.

Table 3

XOR protein in assay (μ g)	Nitrite concentration in assay (mM)	NO release (mV/s)
21.4	0	0.00
21.4	1	53.75
21.4	5	184.8
21.4	10	378.10
21.4	25	407.55
21.4	50	474.05

5 Test 4

The method of Test 1 was repeated with known inhibitors of XOR included in the assay to show that the NO generation was being catalysed by XOR. Two different inhibitors were used. Oxypurinol was used at a

10 concentration of 100 μ M. Oxypurinol is a molybdenum site-specific inhibitor. Diphenyliodonium (DPI) was used at a concentration of 100 μ M. DPI is a FAD site inhibitor. The results are shown in Table 4.

15 Table 4

Inhibitor	NO release (mV/s)
100 μ M Oxypurinol	0.00
100 μ M DPI	0.00

There was no release of NO in the presence of the XOR inhibitors.

Test 5

Full fat milk was assayed with 20mM nitrite and 1mM NADH as described above in Test 1. The milk had a protein content of 3.4g/100ml. 600 μ l of milk was used in each 5 test giving a protein content in each assay of 20.4mg.

The milk was taken and divided into two halves. One was kept at 4°C, and the other at -20°C. Samples of the milk were taken over several days and the generation of NO was 10 investigated using the method described above. The results are given below in Table 5.

Table 5

Day	4°C - NO release (mV/s)	-20°C - NO release (mV/s)
1	77.57	73.00
2	75.50	90.05
3	68.67	52.65
6	626.1	73.35
8	Over 1000	39.20

15

It was found that the milk which was kept at 4°C started to go off after 3 days and that that was accompanied by a large increase in NO release which was not inhibited by 20 100 μ M oxypurinol or DPI. Therefore, when the milk goes off it is probable that bacteria in the milk are starting to produce NO from the nitrite. The milk kept frozen retained its activity and did not go off.

25 Samples of fresh full fat milk assay with 100 μ M Oxypurinol or DPI were tested and found to give no

detectable NO generation. Thus full fat milk does include a source of active XOR which produces NO under hypoxic conditions with nitrite and NADH.

5 Test 6

Human breast milk was assayed with 20mM nitrite and 1mM NADH using the method as described above. The human breast milk was collected on several days post partum and frozen at -20°C. 600µl of milk was used in each test.

- 10 The generation of NO was investigated using the method described above. The results are given below in Table 6.

Table 6

Days post partum	XOR protein content (µg/ml)	NO release (mV/s)
7	411.26	40.45
30	683.05	60.75
36	561.49	42.48
66	305.52	27.80
158	110.84	29.80

15

Test 7

- A selection of formula feeds (formula milks) were taken and assayed with 20mM nitrite and 1mM NADH as described above. The formula milks were tested for the generation of NO. The Cow and Gate Premium was left for 7 days after opening and then tested again. The results are shown in Table 7.

Table 7

Formula feed	NO release (mV/s)
Cow and Gate Premium (fresh)	0.00
Cow and Gate Premium (7 days old)	Over 1000
Milupa Aptamil First with Milupan	0.00
Sma Wysoy	0.00
Sma Gold	0.00
Farleys First	0.00
Milupa Preaptamil with Milupan	0.00

There was no activity found in any of the fresh formula milks. The Cow and Gate formula had gone off after 7 days and the NO release is probably related to bacteria (the activity was not inhibited by 100µM oxypurinol or DPI).

10 Test 8

To obtain cells used in this test, the infective bacterial strain Escherichia coli NCTC 86 (E.coli) was cultured on nutrient agar at 37° until colony formation occurred, usually overnight. This stock culture was used for subsequent experiments including sub-culturing in nutrient broth and plated onto agar weekly. Experimental cultures of E.coli were set up overnight in nutrient broth from single colonies on an agar plate. Cells were harvested and counted using a standard curve of known absorbance at 470nm against viable cell count.

Peroxynitrite was generated by the method of Crow et al, Biochem. 34, p.3544-3552 (1995). In accordance with that

method, a mixture of sodium nitrite and hydrogen peroxide was reacted under acid conditions then immediately quenched by the addition of sodium hydroxide. The concentration of ONOO⁻ formed was measured using an absorption coefficient of 1670 M⁻¹ cm⁻¹ in a spectrophotometer at a wavelength of 303nm. Solutions of different concentrations for use in (a) below were obtained by dilution of the product solution using PBS.

10 8(a) Peroxynitrite effect on cell viability

Cells cultured as described above were diluted to suitable working concentrations (10^4 - 10^5 Cells Ml⁻¹) in sterile phosphate buffered saline (PBS). ONOO⁻ at a range of concentrations from 100 μ m to 0.01 μ m was added as a bolus dose to cells and incubated at room temperature for ten minutes. Aliquots were taken from the cell cultures and plated on to nutrient agar and incubated in a warm room at 37°C overnight. Viable cells formed colonies on the agar and were counted. The number of colonies formed was related to an untreated control and a graph of the results is shown in Figure 1, which illustrates the effect of ONOO⁻ on cell viability. The decrease in viable count with increasing concentration of ONOO⁻ in Fig. 1 is indicative of a profound inhibitory effect.

25 Peroxynitrite has also been shown to reduce viability in S. enteritidis under similar conditions to those indicated above. IC₅₀ values of peroxynitrite in respect of E. coli and S. enteritidis (that is, the concentration that reduces viability to 50% of control viable count of 30 the respective cell type) of 1.402 and 2.026 μ M were determined under the conditions used.

Peroxynitrite-mediated killing has also been indicated in the case of Gram positive bacteria, in a test in which

incubation of *Staphylococcus aureus* with SIN-1 (3-morpholinosydnonimine, which releases both superoxide and NO simultaneously on hydration) showed reduced growth in dependence on the amount of added SIN-1.

5

8(b) Effect of peroxynitrite addition to bovine milk

Commercially produced bovine milk was purchased in semi-skimmed form. Aliquots were taken on day one of experimentation and plated onto nutrient agar and grown

10 overnight at 37°C. The number of colonies formed

following incubation was counted. The remaining milk was divided into three portions after removal of those aliquots. No peroxynitrite was added to the first portion, which was the control. A single bolus dose of

15 100 μ M ONOO⁻ was added to the second portion on day one, and the third portion was treated by addition of a daily bolus dose of 100 μ M ONOO⁻. The portions were stored during the four days of the test at a temperature of 4°C. Each day, aliquots were taken from each portion and

20 cultured overnight at 37°C for viable count determination.

The results are shown in Fig. 2 and demonstrate that ONOO⁻ addition to milk caused a reduction in the number of colony forming units (CFU) over time compared to the

25 control. The single bolus addition reduced the CFU significantly ($p \leq 0.01$) and the multiple dose ONOO⁻ reduced the CFU significantly below control ($p \leq 0.01$) and also significantly below the single dose ONOO⁻ ($p \leq 0.05$).

Although the contaminants were not formally identified,

30 it was postulated that they included at least *Lactobacilli* sp., that being a cell type often present in milk.

8(c) Effect of xanthine oxidase derived species on cell viability

E.coli were cultured as described above. Aliquots were taken and incubated with a reaction system consisting of 5 bovine Xanthine oxidase (XO) ($53.2 \mu\text{g ml}^{-1}$), nicotinamide adenine dinucleotide in reduced form (NADH) ($300 \mu\text{M}$), sodium nitrite, (NaNO_2) 1mM and oxygen at a range of concentrations. Desired oxygen concentrations were generated by delivery into the system of a mixture of 10 oxygen and nitrogen in appropriate proportions and determined using a Clark-type O_2 electrode. This reaction was followed at 37°C for 30 min with mixing before an aliquot was taken and plated onto agar and incubated in a warm room at 37°C . Viable cells formed colonies on the 15 agar and were counted. Viable cell counts were performed in triplicate and the results expressed as a percentage viable count in each case related to a non enzyme control of the same oxygen concentration. The results are shown in Fig. 3, which suggest that XO-mediated killing of 20 cells is occurring. The most effective killing (indicated by the lowest viable cell count) is at an oxygen concentration of approximately 3% of saturation. The range of oxygen tensions used covers those in which XO has previously been considered to be active, namely 25 superoxide generation (21% O_2 saturation) and nitric oxide production (0% O_2 saturation). A certain amount of killing is seen at both of these extremes as compared with control samples. However, it is only at an intermediate oxygen concentration that the greatest 30 amount of killing is observed. This suggests a role for peroxynitrite mediated killing which has been generated in this system by the enzyme xanthine oxidase.

Corresponding data obtained in respect of *S. enteritidis* indicated a peak killing oxygen concentration of 0% for that cell type. For both *E. coli* and *S. enteritidis* the viability increases with oxygen concentration with little or no killing above about 8% oxygen, although some limited killing (about 5% and about 10% for the respective cell types) is again observed at higher oxygen concentrations of about 21%.

Replacement of NADH in the above method by 100 μ M hypoxanthine, with a sodium nitrite concentration of 2.5 μ M led to slightly higher peak killing oxygen concentrations (6.4% for *E. coli* and 1.5% for *S. enteritidis*). More limited killing was also observed using xanthine instead of hypoxanthine. The XO/hypoxanthine combination was also found to reduce the growth rate of *Lactobacillus* in a dose dependent manner for both hypoxanthine and XO. Addition to the XO/hypoxanthine system of superoxide dismutase at oxygen concentrations in the range of from 0 to 2% was found to increase the amount of measurable NO (as a result of removal of superoxide by superoxide dismutase), providing a further indication of the hypothesis that peroxynitrite formation from NO and superoxide occurs in the XO/hypoxanthine system.

25

8(d) Effect of peroxynitrite scavenger on bacterial growth

E. coli were seeded into nutrient broth at 2.10^7 cell ml $^{-1}$ and incubated at 37°C under atmospheric air conditions (that is, 21% oxygen saturation). Four separate test samples of volume 1 ml were prepared by addition at 1 hour of incubation as follows:

- 1 Peroxynitrite at concentration 100 μ M.

2 Peroxynitrite at 100 μ M and quercetin (peroxynitrite scavenger) at 100 μ M.

3 Xanthine oxidase (53.2 μ g) and xanthine at 100 μ M.

4 Xanthine oxidase (53.2 μ g) and NADH at 100 μ M.

5

Corresponding controls were also prepared, and the growth curves generated over time determined by monitoring absorbance. Sample (1) showed strong killing, but the presence of quercetin (sample (2)) had a clear effect in reducing killing, pointing towards peroxynitrite mediation of killing. XO/NADH (sample (4)) and XO/xanthine (sample (3)) showed limited, but significant, growth retardation effects.

The results of parts (a), (b) and (d) of this test appear to confirm the bactericidal potency of the peroxynitrite species. Part (c) above supports the hypothesis that, under appropriate conditions, XOR can catalyse production both of superoxide and of NO, interaction of those two products giving rise to peroxynitrite, and possibly other interaction products that may have similar bactericidal activity to peroxynitrite. The oxygen concentrations of under 8% at which maximum killing was observed is believed to be similar to that in the neonatal gut.

25 8(e) Effect of hypoxanthine addition on bacterial growth in pateurised milk.

Pasteurised semi skimmed milk 1 ml was aliquoted into 7 sterile plastic bijou bottles comprising control and treated hypoxanthine (Hxan) groups. To the control group 30 at day 0 was added 10 μ l of sterile ddH₂O and to the treated group 10 μ l of hypoxanthine solution was added to give a final concentration of 100 μ M. The samples were stored refrigerated at 4-8°C until required on a specific

day when a control and treated sample was incubated at 37°C for 30 minutes. A 100 μ l aliquot was taken from each sample and spread onto nutrient agar which was then incubated over night at 37°C. The total number of colonies formed regardless of type was counted and expressed for each treatment as the colony forming units per ml of the original test sample (CFU ml⁻¹). The results are shown in Fig. 4.

The control group showed significant colony formation from day 1. The effect of the addition of hypoxanthine was to reduce the total number of colonies formed for the length of the experiment (8 days).

15 **8(f) Effect of XO and hypoxanthine incubation on bacterial growth rate.**

Bacteria were seeded into nutrient broth (NB) and grown over night at 37°C. The culture was then counted and normalised to give a final cell concentration of 1.8x10⁷ cells well⁻¹ into the wells of a 96 well plate in fresh nutrient broth. The optical density of each well was monitored every 15 minutes as a measure of the growth rate of each bacterial species. Growth curves were generated for each species and the maximal rate of growth (logarithmic phase) was measured. Cells were treated to a range of experimental conditions in which the growth rate of cells was related to a control of untreated cells. The results were expressed as a percentage of the growth rate of the control cells.

(i) At a fixed concentration of hypoxanthine (100 μ M) a range of purified XO protein concentrations were added at time 0 minutes. The optical density was followed and the growth rate calculated. The effect of enzyme concentration is shown in Fig. 5

for *Staphylococcus aureus* 6751 and *Lactobacillus casei* 6375.

The growth rate of both *Staphylococcus* and *Lactobacilli* was reduced compared to the control.

5 *Lactobacillus* growth rate was reduced with a half maximal concentration of XO (that is, the concentration at which the cell growth was 50% of control) being about 14 μ g. A less marked growth inhibition was observed for *Staphylococcus*.

10 (ii) The growth rate was also measured in relation to the concentration of hypoxanthine, using 30 μ g of XO with cells seeded as described above. Fig. 6 shows the effect of hypoxanthine concentration on bacterial growth. Hypoxanthine in the presence of XO reduced the growth rate of both bacterial species with greatest effect on the *Lactobacillus*. The half maximal hypoxanthine dose at 30 μ g XO was 103.5 μ M.

15 (iii) To show that the effect of XO and Hypoxanthine addition was due to the enzymically derived products, oxypurinol at a range of concentrations was added to the cells in the presence of 30 μ g XO and 200 μ M hypoxanthine. Fig. 7 shows its effect on the growth rate of *Lactobacillus*.

20 Oxypurinol had no effect on growth rate when added at the highest concentration when added alone. However the effect of oxypurinol was to reduce the effect of XO/hypoxanthine growth inhibition in a dose dependent manner.

25 (iv) The effect of XO hypoxanthine addition was measured on the growth rate of a range of bacterial species with 30 μ g XO at varying

hypoxanthine concentrations using cells seeded as described above. The results of this study are shown in Fig. 8.

5 8(g) Effect of H₂O₂ and peroxynitrite on the growth rate
of bacteria

To determine the effect of possible enzymically generated radical species cells were grown in the presence of hydrogen peroxide or peroxynitrite. Cells of various 10 species were grown as previously described and a bolus addition of either H₂O₂ or peroxynitrite was added at the beginning of logarithmic growth, previous experiments having showed this treatment as the most effective. The cell growth was determined and plotted against the 15 concentration of H₂O₂ or peroxynitrite, as appropriate, and the half maximal concentration of H₂O₂ or peroxynitrite was determined. The results are summarised in Table 8, in which corresponding half maximal concentrations for the XO/hypoxanthine system are also given.

Table 8

Species	Half maximal concentration		
	XO/Hxan (μM Hypoxanthine)	H ₂ O ₂ (μM)	ONOO - (μM)
<i>Bacillus sp</i>	39.8	77.6	
<i>Micrococcus sp</i>	25.1	19.5	
<i>Lactobacillus casei</i>	103.5	304.8	55
<i>Staphylococcus aureus</i>		-	290
<i>E. coli</i>			1.4
<i>Salmonella enteritidis</i>			2.0

As shown in Table 8, the half maximal concentrations for peroxyxnitrite in respect of Lactobacillus casei is much lower than for H₂O₂. In respect of S. aureus, the growth inhibition in the presence of H₂O₂ was very limited, with 5 50% growth reduction not being observed at the concentration ranges used.

The following Example illustrates the invention:

10 **Example 1**

The effect of the addition of XOR to formula feed on the generation of NO was investigated. Different compositions comprising one or more of buttermilk, formula feed, XOR, nitrite and NADH were studied under 15 hypoxic conditions.

The samples were tested for NO generation using the method described above.

To the "milk" bijou were added either 598μl Cow and Gate formula feed and 2μl XOR or 100μl buttermilk and 20 500μl 1X PBS to give a total volume in the "milk" bijou of 600μl in each case.

Table 9

Sample	20mM nitrite added?	1mM NADH added?	NO release (mV/s)
Formula feed and XOR	Yes	Yes	247.3
Formula feed and XOR	No	No	0.0
Formula feed and XOR	Yes	No	0.0
Formula feed and XOR	No	Yes	0.0
Formula feed and 1X PBS	Yes	Yes	0.0
Buttermilk	Yes	Yes	379.1

Table 9 shows that where no XOR is added to the formula feed, there is no generation of NO. That is consistent with the applicant's findings that formula feeds do not contain active XOR.

5 The addition of XOR to the formula feed in the presence of nitrite and NADH led to the generation of NO. The omission of either the nitrite or the NADH gave no NO generation. As indicated above, it is believed that both a source of nitrite and an electron donor substrate will
10 be available *in vivo* in the GI tract and that in many cases specific further addition of nitrite and/or NADH (or other substrate) will not be required.

Buttermilk alone, without the addition of any of XOR, nitrite or NADH, led to the generation of NO. As
15 indicated above, buttermilk contains active XOR as well as a source of nitrite, and an electron donor substrate.

Claims:

1. A formulation for use as a bactericidal agent in the human or animal digestive system, the formulation including active xanthine oxidoreductase (XOR).

5 2. A formula feed formulation or enteral feed formulation for administration to a human or animal, the formulation including active xanthine oxidoreductase (XOR).

10 3. A formulation according to claim 2, in which the formulation is for use as formula feed.

4. A formulation according to any one of claims 1 to 3, in which the concentration of XOR exceeds the normal physiological concentration of XOR.

15 5. A formulation according to any one of claims 1 to 4, in which the formulation includes from 50 to 150 μ g/ml of XOR.

6. A formulation according to any one of claims 1 to 5, in which the formulation includes buttermilk, the buttermilk including active XOR.

20 7. A formulation according to any one of claims 1 to 6, in which the formulation is in liquid form.

8. A formulation according to any one of claims 1 to 7, the formulation further including one or more electron donors.

25 9. A formulation according to any one of claims 1 to 8, the formulation further including one or more electron acceptors.

10. A combination product for use in the preparation of a formulation according to any one of claims 1 to 9,

30 in which the product comprises two separate portions, the first portion including active XOR and the second portion comprising substantially no active XOR.

11. A combination product according to claim 10, in which the second portion is in the form of a powder.
12. A formulation according to claim 10 or claim 11, in which the second portion has been heat treated.
- 5 13. A formulation according to any one of claims 10 to 12, in which the first portion has been pasteurised.
14. A formulation according to any one of claims 10 to 13, in which the first portion is in a first container, the second portion is in a second container.
- 10 15. A composition for addition to a formulation for use as feed, the composition comprising active XOR in combination with one or more electron donors and/or one or more electron acceptors.
16. A composition according to claim 15, the
15 composition comprising buttermilk.
17. A composition according to claim 15 or claim 16, the composition being in the form of a powder.
18. A method of making a formulation for use as feed, the method comprising the step of adding a composition comprising active XOR.
- 20 19. A method according to claim 18, the composition being according to any one of claims 15 to 17.
20. A method according to claim 19 or claim 20, the method comprising the steps of:
 - 25 a. preparing a first portion of the formulation, the first portion comprising a composition including active XOR; and
 - b. preparing a second portion of the formulation, the first portion and second portion being separate from each other for subsequent mixing to form the formulation.
- 30 21. A method according to claim 20, in which the first portion comprises lyophilised buttermilk.

22. A method according to claim 20 or claim 21, in which the second portion comprises a treated feed composition.

23. Use of active XOR in the treatment of
5 gastrointestinal (GI) infection.

24. Use of active XOR in the treatment of Scours disease.

25. Use of active XOR in the killing of bacteria.

26. Method of feeding a patient with enteral feed, in
10 which the enteral feed includes active XOR.

27. Method of feeding an infant with formula feed, in which the formula feed includes active XOR.

28. A formulation comprising XOR substantially as described in Example 1 herein.




Fig. 1




Fig. 2




Fig.3




Fig.4

3 / 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 March 2000 (09.03.2000)

PCT

(10) International Publication Number
WO 00/11965 A3

- (51) International Patent Classification⁷: **A61K 38/44, 35/20, A23C 17/02, 11/00, A61P 31/04**
- (21) International Application Number: **PCT/GB99/02845**
- (22) International Filing Date: 27 August 1999 (27.08.1999)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
9818913.7 28 August 1998 (28.08.1998) GB
9827243.8 10 December 1998 (10.12.1998) GB
- (71) Applicant (for all designated States except US): **THE UNIVERSITY OF BATH [GB/GB]**; Claverton Down, Bath BA2 7AY (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BLAKE, David, Russell [GB/GB]**; The Ground Floor Flat, 16 The Circus, Bath BA1 2ET (GB). **STEVENS, Clifford, Robert [GB/GB]**; 49 The Old Batch, Bradford on Avon, Wiltshire BA15 1TL (GB). **EISENTHAL, Robert [GB/GB]**; 20 Lansdown Lane, Bath BA1 4LR (GB). **HARRISON, Roger [GB/GB]**; 16 Grove Leaze, Bradford on Avon, Wiltshire BA15 1PH (GB). **MILLAR, Timothy, Mark [GB/GB]**; 139 Langdon Road, Southdown, Bath BA2 1LT
- (74) Agents: **HUMPHREYS, Ceris, Anne et al.; Abel & Imray, 20 Red Lion Street, London WC1R 4PQ (GB)**.
- (81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
23 August 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/11965 A3

(54) Title: INGESTIBLE COMPOSITIONS COMPRISING ANTIBACTERIAL AGENTS

(57) Abstract: A formulation for use as a bactericidal agent in the human or animal digestive system includes xanthine oxidoreductase. The formulation may especially be in the form of a formula feed formulation or enteral feed formulation for administration to a human or animal. The formulation is capable of functioning as a "natural antibiotic" to prevent or reduce bacterial infection within the gut, especially the neonatal gut.

INTERNATIONAL SEARCH REPORT

Int'l Application No.
PCT/GB 99/02845

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/44 A61K35/20 A23C17/02 A23C11/00 A61P31/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A23K A23L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 645 834 A (COCKRUM RICHARD H) 8 July 1997 (1997-07-08) column 2, line 4 - line 29; claim 17	1-7, 10-14, 18, 20-22,28
X	US 5 310 541 A (MONTGOMERY ROBERT E) 10 May 1994 (1994-05-10) the whole document	1-8, 10-28
X	WO 93 23080 A (FOSSEL ERIC T ;BETH ISRAEL HOSPITAL (US)) 25 November 1993 (1993-11-25) page 4, line 22 -page 6, line 2 page 18, line 11 - line 18	1 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

- "T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "Z" document member of the same patent family

Date of the actual completion of the International search

20 March 2000

Date of mailing of the International search report

06/04/2000

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3018

Authorized officer

Fernandez y Branas, F

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/GB 99/02845

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EP 0 518 445 A (GIST BROCADES NV) 16 December 1992 (1992-12-16)</p> <p>page 4, line 9 - line 28 page 6, line 1 - line 3 page 6, line 44 - line 48; claim 17</p> <hr/>	1-7, 10-14, 18-28
A	<p>EP 0 477 143 A (IDI FARMACEUTICI SPA) 25 March 1992 (1992-03-25)</p> <p>the whole document</p> <hr/>	1-28
A	<p>MILLAR T.M. ET AL: "Xanthine oxidase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions" FEBS LETTERS, May 1998 (1998-05), pages 225-228, XP002133526</p> <p>cited in the application</p> <p>the whole document</p> <hr/>	1-28

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 99/02845

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 23-27 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte. onal Application No

PCT/GB 99/02845

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 5645834	A	08-07-1997		CA 2148963 A GB 2289278 A, B IE 950335 A		10-11-1995 15-11-1995 29-11-1995
US 5310541	A	10-05-1994		AU 4839893 A CA 2143111 A DE 69326955 D EP 0658096 A WO 9405252 A		29-03-1994 17-03-1994 09-12-1999 21-06-1995 17-03-1994
WO 9323080	A	25-11-1993		AU 4375293 A		13-12-1993
EP 0518445	A	16-12-1992		AT 136740 T AU 652279 B AU 2275392 A DE 69209894 D DE 69209894 T IE 74397 B JP 6500700 T WO 9222221 A NZ 243106 A US 5747078 A		15-05-1996 18-08-1994 12-01-1993 23-05-1996 05-09-1996 30-07-1997 27-01-1994 23-12-1992 27-09-1994 05-05-1998
EP 0477143	A	25-03-1992		IT 1241994 B AT 136787 T DE 69118796 D DE 69118796 T DK 477143 T ES 2086518 T		02-02-1994 15-05-1996 23-05-1996 24-10-1996 08-07-1996 01-07-1996